2 weeks Ago By Defense World Staff
InflaRx ( NASDAQ:IFRX – Get Free Report ) will be posting its quarterly earnings results before the market opens on Friday, November 8th. Analysts expect InflaRx to post earnings of ($0.27) per share for the quarter.
InflaRx ( NASDAQ:IFRX – Get Free Report ) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.26) earnings per share for the quarter, missing the consensus estimate of ($0.
21) by ($0.05). InflaRx had a negative return on equity of 47.
03% and a negative net margin of 44,046.09%. The firm had revenue of $0.
01 million during the quarter, compared to analysts’ expectations of $0.04 million. On average, analysts expect InflaRx to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
InflaRx Stock Performance Shares of NASDAQ IFRX opened at $1.53 on Thursday. The company has a 50 day simple moving average of $1.
53 and a two-hundred day simple moving average of $1.51. The company has a market capitalization of $90.
09 million, a price-to-earnings ratio of -1.72 and a beta of 1.57.
InflaRx has a fifty-two week low of $1.14 and a fifty-two week high of $2.10.
Analyst Upgrades and Downgrades Read Our Latest Research Report on IFRX InflaRx Company Profile ( Get Free Report ) InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States.
The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. See Also Five stocks we like better than InflaRx What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story What a Trump Win Looks Like for the Market Now and Into 2025 Investing in Commodities: What Are They? How to Invest in Them Russell 2000 Surge Post-Election: How to Play the Small-Cap Pop 3 Small Caps With Big Return Potential Macro Headwinds Send Microchip Technology Stock to the Buy Zone Receive News & Ratings for InflaRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InflaRx and related companies with MarketBeat.
com's FREE daily email newsletter ..
